The definition of a rare disease varies internationally. In the U.S., it’s a condition affecting fewer than 200,000 people, while the World Health Organization sets the threshold at less than 6.5 to 10 per 10,000 people, and the European Union at 5 in 10,000. About 80% of rare diseases are genetic in origin.
Rare diseases impact 8% to 10% of the global population, presenting unique challenges. Low prevalence and limited awareness lead to misdiagnosis and delayed treatment, and patients often receive only symptomatic care due to limited treatment options. Clinical trials for rare diseases face difficulties in participant recruitment, impacting the development of evidence-based treatments. Furthermore, pharmaceutical companies are often reluctant to invest in therapies for rare diseases due to high costs and low profitability.
Collaboration and knowledge sharing among rare disease researchers are challenging due to their global distribution. Regulatory processes for treatments are complex, further hindering research progress. However, patient registries, which collect uniform data to evaluate patient outcomes, are proving beneficial. These registries assist in identifying disease patterns, enhancing recruitment for studies, supporting regulatory decisions, influencing public policy, and creating support networks for patients and caregivers.
Government initiatives are crucial in rare disease research, including awareness programs, legislative support, forming patient registries, and providing research grants. The Orphan Drug Act of 1983 is a notable example of legislation promoting the development of rare disease therapy—international collaboration, such as the International Rare Disease Research Consortium, further addresses occasional disease challenges.
Strategies to sustain and enhance patient registries’ impact include securing diverse funding sources, fostering stakeholder collaborations, and leveraging technology. This collective effort is vital for advancing medical research and improving outcomes for rare disease patients worldwide.
To read more, click here.
[Source: Pharmacy Times, December 14th, 2023]